Genital Herpes - Pipeline Review, H1 2015

Published: Jan, 2015 | Pages: 64 | Publisher: Global Markets Direct
Industry: Pharmaceuticals & Healthcare | Report Format: Electronic (PDF)

Genital Herpes - Pipeline Review, H1 2015

Summary

Global Markets Direct's, 'Genital Herpes - Pipeline Review, H1 2015', provides an overview of the Genital Herpes's therapeutic pipeline.

This report provides comprehensive information on the therapeutic development for Genital Herpes, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Genital Herpes and special features on late-stage and discontinued projects.

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct's team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

- The report provides a snapshot of the global therapeutic landscape of Genital Herpes
- The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities 
- The report reviews key players involved in the therapeutics development for Genital Herpes and enlists all their major and minor projects
- The report summarizes all the dormant and discontinued pipeline projects 
- A review of the Genital Herpes products under development by companies and universities/research institutes based on information derived from company and industry-specific sources
- Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages
- A detailed assessment of monotherapy and combination therapy pipeline projects
- Coverage of the Genital Herpes pipeline on the basis of target, MoA, route of administration and molecule type
- Latest news and deals relating related to pipeline products

Reasons to buy

- Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Develop strategic initiatives by understanding the focus areas of leading companies
- Identify and understand important and diverse types of therapeutics under development for Genital Herpes
- Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline
- Devise corrective measures for pipeline projects by understanding Genital Herpes pipeline depth and focus of Indication therapeutics
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

 Table of Contents
Table of Contents 2
List of Tables 4
List of Figures 5
Introduction 6
Global Markets Direct Report Coverage 6
Genital Herpes Overview 7
Therapeutics Development 8
Pipeline Products for Genital Herpes - Overview 8
Pipeline Products for Genital Herpes - Comparative Analysis 9
Genital Herpes - Therapeutics under Development by Companies 10
Genital Herpes - Therapeutics under Investigation by Universities/Institutes 11
Genital Herpes - Pipeline Products Glance 12
Clinical Stage Products 12
Early Stage Products 13
Genital Herpes - Products under Development by Companies 14
Genital Herpes - Products under Investigation by Universities/Institutes 15
Genital Herpes - Companies Involved in Therapeutics Development 16
Agenus, Inc. 16
AiCuris GmbH & Co. KG 17
Foamix Pharmaceuticals Ltd. 18
Genocea Biosciences, Inc. 19
NanoViricides, Inc. 20
Starpharma Holdings Limited 21
Vical Incorporated 22
Genital Herpes - Therapeutics Assessment 23
Assessment by Monotherapy Products 23
Assessment by Target 24
Assessment by Mechanism of Action 26
Assessment by Route of Administration 27
Assessment by Molecule Type 29
Drug Profiles 31
acyclovir - Drug Profile 31
Product Description 31
Mechanism of Action 31
R&D Progress 31
astodrimer - Drug Profile 32
Product Description 32
Mechanism of Action 32
R&D Progress 32
GEN-003 - Drug Profile 34
Product Description 34
Mechanism of Action 34
R&D Progress 34
genital herpes vaccine - Drug Profile 36
Product Description 36
Mechanism of Action 36
R&D Progress 36
genital herpes vaccine [HSV-2] - Drug Profile 37
Product Description 37
Mechanism of Action 37
R&D Progress 37
HerpeCide-I - Drug Profile 38
Product Description 38
Mechanism of Action 38
R&D Progress 38
herpes simplex vaccine - Drug Profile 39
Product Description 39
Mechanism of Action 39
R&D Progress 39
HSV [type 2] vaccine - Drug Profile 40
Product Description 40
Mechanism of Action 40
R&D Progress 40
pritelivir - Drug Profile 41
Product Description 41
Mechanism of Action 41
R&D Progress 41
VCLHB-01 - Drug Profile 42
Product Description 42
Mechanism of Action 42
R&D Progress 42
VCLHM-01 - Drug Profile 43
Product Description 43
Mechanism of Action 43
R&D Progress 43
Genital Herpes - Recent Pipeline Updates 44
Genital Herpes - Dormant Projects 53
Genital Herpes - Discontinued Products 54
Genital Herpes - Product Development Milestones 55
Featured News & Press Releases 55
Jan 07, 2015: Genocea Completes Enrollment Early in Phase 2 Dose Optimization Trial of GEN-003 for Treatment of Genital Herpes 55
Jun 26, 2014: Agenus Vaccine Shows Significant Reduction in Viral Burden After HerpV Generated Immune Activation 55
Nov 07, 2013: Agenus' HerpV Therapeutic Vaccine for Genital Herpes Meets Primary Endpoint in Randomized Phase 2 Trial 56
Feb 27, 2013: Agenus's HerpV Phase II Study To Treat Genital Herpes Completes Enrollment 57
Jan 29, 2013: AiCuris Surpasses 50% Enrollment Milestone In Phase II Trial For Herpes Drug Pritelivir 58
Nov 27, 2012: AiCuris Starts Second Clinical Efficacy Trial With pritelivir 59
Oct 23, 2012: Agenus Commences Phase II Study Of HerpV Vaccine For Treatment Of Genital Herpes 59
Aug 07, 2012: AiCuris To Present Data On AIC316 At International Herpesvirus Workshop 60
Apr 16, 2012: AiCuris To Report AIC316 Phase II trial Data At International Meetings 61
Sep 26, 2011: Agenus Announces Positive Phase I Study Results Of HerpV In Genital Herpes 61
Appendix 63
Methodology 63
Coverage 63
Secondary Research 63
Primary Research 63
Expert Panel Validation 63
Contact Us 63
Disclaimer 64

List of Tables
Number of Products under Development for Genital Herpes, H1 2015 8
Number of Products under Development for Genital Herpes - Comparative Analysis, H1 2015 9
Number of Products under Development by Companies, H1 2015 10
Number of Products under Investigation by Universities/Institutes, H1 2015 11
Comparative Analysis by Clinical Stage Development, H1 2015 12
Comparative Analysis by Early Stage Development, H1 2015 13
Products under Development by Companies, H1 2015 14
Products under Investigation by Universities/Institutes, H1 2015 15
Genital Herpes - Pipeline by Agenus, Inc., H1 2015 16
Genital Herpes - Pipeline by AiCuris GmbH & Co. KG, H1 2015 17
Genital Herpes - Pipeline by Foamix Pharmaceuticals Ltd., H1 2015 18
Genital Herpes - Pipeline by Genocea Biosciences, Inc., H1 2015 19
Genital Herpes - Pipeline by NanoViricides, Inc., H1 2015 20
Genital Herpes - Pipeline by Starpharma Holdings Limited, H1 2015 21
Genital Herpes - Pipeline by Vical Incorporated, H1 2015 22
Assessment by Monotherapy Products, H1 2015 23
Number of Products by Stage and Target, H1 2015 25
Number of Products by Stage and Mechanism of Action, H1 2015 26
Number of Products by Stage and Route of Administration, H1 2015 28
Number of Products by Stage and Molecule Type, H1 2015 30
Genital Herpes Therapeutics - Recent Pipeline Updates, H1 2015 44
Genital Herpes - Dormant Projects, H1 2015 53
Genital Herpes - Discontinued Products, H1 2015 54